Abstract: Provided are methods of treating cancer, and/or the side effects of cancer therapy, involving the administration of glutamine, optionally in combination with a carbohydrate carrier that enhances the absorption of glutamine.

Abstract: Provided are methods of treating cancer, and/or the side effects of cancer therapy, involving the administration of glutamine, optionally in combination with a carbohydrate carrier that enhances the absorption of glutamine.

Abstract: Provided is a composition and a method for increasing cellular uptake of bioactive agents, particularly those compounds termed “small molecules” into the cells of mammalian tissue, such as the epithelial cells of the mucosa.

Abstract: The invention provides a method of preparing anhydrous disodium pamidronate or an aqueous disodium pamidronate solution for pharmaceutical use.

Abstract: Provided is a composition and a method for increasing cellular uptake of bioactive agents, particularly those compounds termed “small molecules” into the cells of mammalian tissue, such as the epithelial cells of the mucosa.

Abstract: Provided is a composition and a method for increasing cellular uptake of bioactive agents, particularly those compounds termed “small molecules” into the cells of mammalian tissue, such as the epithelial cells of the mucosa.

Abstract: The invention provides amorphous disodium pamidronate having no more than about 1-2 wt-% water.

Abstract: The invention provides a therapeutic calcitriol solution which is suitable for packaging into pharmaceutical vials without producing discoloration of the antioxidant component of the solution.

Abstract: The invention includes a method for the preparation of disodium pamidronate comprising: (a) preparing a stirred slurry of pamidronate in water, (b) adding a solution of sodium hydroxide to give a clear solution at pH of about 6.5, (c) filtering the solution and (d) freezing and lyophilizing the solution to give an amorphous essentially anhydrous disodium pamidronate which contains .ltoreq.2 wt-% water.

Abstract: Lipid emulsion form compositions have been formulated and presented to eliminate adverse injection site reactions associated with the intravenous administration of certain sparingly water soluble, hydrophobic, ionizable drugs in mammals and to provide a solubilized drug form for oral, parenteral or intraarticular administration which enhances drug absorption and the therapeutic efficacy of the drug.

Abstract: This disclosure describes quick breaking, in vivo, intravenous, intramuscular, intraarticular fat emulsion compositions which incorporate the use of benzyl alcohol as a consurfactant and/or a cosolvent in combination with materials such as synthetic surfactants, e.g. sorbitan triisostearate, triglycerol diisostearate or triglycerol pentaoleate; naturally occurring vegetable oils, e.g. sesame oil, and soybean oil; natural lecithins such as egg lecithin or soy lecithin; saturated or unsaturated aliphatic acids, e.g. oleic acid, hexanoic acid and linolenic acid; and other excipients such as glycerine, polyvinylpyrrolidone, Pluronic.RTM. F-68 and di-.alpha.-tocopherol.

Abstract: This invention concerns novel water-soluble salts and compositions of the antitumor agent 4'-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA). More particularly, there are provided (1) the mono- and dipyroglutamate salts of m-AMSA and (2) compositions of m-AMSA with pyroglutamic acid. The novel salts and compositions provided enable m-AMSA to be administered as an aqueous solution without the necessity of using dimethylacetamide as a pharmaceutical vehicle.

Abstract: BBM-928A solutions suitable for parenteral use in animal experiments and having concentrations in the range of 1 mg/ml to 5 mg/ml are described.